The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

Poster Presenter: Emre Sahin, MD, Postdoctoral Research Fellow, Hospital for Special Surgery

Poster Title: The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

Poster Session A: 10:30 a.m.–12:30 p.m. on Sunday, October 26

What is your poster about?

“APS ACTION is an international antiphospholipid syndrome research network, and APS ACTION researchers have established a multicenter international registry to study the long-term outcomes of patients who are persistently positive for antiphospholipid antibodies (aPLs). Our poster focuses on the prevalence of heritable thrombophilias in the APS ACTION registry, and we analyze how heritable thrombophilias, alone or in combination, are associated with thrombosis risk in this patient population.”

Why did you decide to investigate this topic?

“We decided to investigate this topic because, although aPLs are recognized risk factors for thrombosis, the contribution of heritable thrombophilias in aPL-positive patients remains unclear. Previous studies have been limited by small sample sizes and conflicting results, so our study aims to provide a clearer understanding of the prevalence and clinical impact of these additional risk factors.”

What are you working on next related to this research?

“We plan to focus on presenting the role of heritable thrombophilias in a way that is more understandable and clinically relevant for rheumatologists, as this area is often discussed outside of rheumatology. In addition to this research, there are several ongoing APS ACTION studies focusing on the registry analysis (some presented during ACR Convergence), in which I am also involved.”

What excites you most about your work?

“To investigate how different risk factors, such as heritable thrombophilias and aPLs, may interact to further increase thrombotic risk. Being able to study this question in the unique APS ACTION cohort provides a valuable opportunity to gain insights that smaller studies could not demonstrate.”

What are you most looking forward to at ACR Convergence 2025 in Chicago?

“Sharing my own work with leading experts in the field, learning from the insightful studies presented by other researchers, and connecting with peers at ACR Convergence 2025.”